Induction immunochemotherapy followed by definitive radiotherapy in patients with limited-stage small cell lung cancer: a multicenter study

Efficacy of the induction immunochemotherapy followed by definitive radiotherapy and exploratory subgroup survival analysis. (A, B) PFS and OS of patients in the I-CRT and CRT groups. (C) Tumor response of patients in the I-CRT and CRT groups. (D) Waterfall plot of the best overall response from baseline in the I-CRT group. (E, F) PFS and OS of patients in the CCRT and SCRT groups. (G, H) PFS and OS of patients in the “once-daily” and “twice-daily” groups. (I, J) PFS and OS of patients in the “1–3 cycles” and “4–6 cycles” groups. (K–N) Dosimetric parameters of patients in the “1–3 cycles” and “4–6 cycles” groups, including MLD (K), V5 (L), V20 (M), and V30 (N). CCRT, concurrent chemoradiotherapy; MLD, mean lung dose; OS, overall survival; PFS, progression-free survival; SCRT, sequential chemoradiotherapy; V5, volume of lung parenchyma receiving ≥ 5 Gy; V20, volume of lung parenchyma receiving ≥ 20 Gy; V30, volume of lung parenchyma receiving ≥ 30 Gy.